Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine whether a test titration regimen of ACTIQ
treatment will reduce the number of inadequately managed episodes of breakthrough pain for an
individual patient by attaining a successful dose of ACTIQ treatment more quickly. The
successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after
a single administration, as assessed by the patient.